Key Biosimilars Events of April 2026

Why It Matters

Accelerated approvals and high‑value acquisitions deepen market competition, promising lower biologic prices and faster patient access worldwide.

Key Takeaways

• EC approved Poherdy (pertuzumab) biosimilar, expanding European market
• Biocon launched Bosaya and Aukelso biosimilars in US, increasing denosumab competition
• Amneal to acquire Kashiv Biosciences for $1.1B, boosting US biosimilar pipeline
• Sun Pharma's $11.75B Organon deal positions it in top‑10 global biosimilars
• Denosumab biosimilars approved in Canada and China, widening patient access

Pulse Analysis

April 2026 marked a surge in biosimilar regulatory activity, with the European Commission granting marketing authorisation for Poherdy, a pertuzumab biosimilar, and Tuyory, a tocilizumab copy of RoActemra. Across the Atlantic, Health Canada approved Apotex’s Denoza and Biocon’s Bosaya and Vevzuo, while China’s NMPA cleared IND applications for Henlius’ HLX319 (a Phesgo biosimilar) and HLX05‑N (an Erbitux biosimilar). These approvals span oncology, rheumatology and bone‑health indications, expanding therapeutic choice in three major markets and reinforcing the global shift toward cost‑effective biologics.

The commercial launches underscore the growing depth of the biosimilar pipeline. Biocon’s entry into the U.S. denosumab market with Bosaya and Aukelso introduces interchangeable options for osteoporosis and bone‑metastasis care, directly challenging Amgen’s Prolia and Xgeva. Meanwhile, CuraTeQ’s Phase‑III data for BP11, an omalizumab biosimilar, demonstrated clinical equivalence to Xolair, paving the way for a filing in the EU and the United States later this quarter. Together with multiple denosumab biosimilars cleared in Canada and China, the expanding portfolio promises price competition that could translate into measurable savings for health systems and patients.

Strategic M&A activity amplified the consolidation trend. Amneal’s $1.1 billion acquisition of Kashiv Biosciences adds a robust development platform and manufacturing capacity, strengthening Amneal’s foothold in the U.S. biosimilar market. Sun Pharma’s $11.75 billion purchase of Organon not only broadens its innovative medicines portfolio but also secures a top‑ten global position in biosimilars, leveraging Organon’s established pipeline. These deals signal that large pharmaceutical players are betting on scale and diversified biosimilar offerings to capture market share, accelerate regulatory pathways, and meet rising demand for affordable biologic therapies.